Last reviewed · How we verify
Elranatamab injection (elranatamab-injection)
At a glance
| Generic name | elranatamab-injection |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Bispecific antibody |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- Elranatamab in R/R Multiple Myeloma (PHASE2)
- ELISA in Relapsed/Refractory MM (PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (PHASE1)
- A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (PHASE1)
- Elranatamab in Relapsed/Refractory Multiple Myeloma (PHASE2)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elranatamab injection CI brief — competitive landscape report
- Elranatamab injection updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI